Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
PaperCitations, authors & open-access status
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 17 citations, 2023 year and hybrid oa status.
17
Citations
2023
Year
hybrid
OA Status